Therapeutic role of growth factors in treating diabetic wound

Table 4 Clinical trials of growth factors in diabetic wounds

Therapeutic agents	Delivery system and route	Response on wound closure	Ref.
EGF	Cream	Significantly improve wound healing rates and reduced the risk of amputation	[371]
bFGF	CGS/suture to surrounding skin	Significant wound improvement within 14 d	[372]
PDGF	Topical gel wound dressing	Reduce healing time by 30%	[373]
PDGF	Topical becaplermin gel	Improve wound healing by 35%	[240]
bFGF	0.0005% benzalkonium chloride in saline/spray on the wound	Significantly reduce wound area	[374]
rhVEGF	Methylcellulose gel/apply evenly to wounds and edges	Significantly increase incidence of complete wound healing	[375]
PDGF	Becaplermin gel/topical apply	The incidence of complete closure was significantly increased by 43%	[241]
EGF	Intralesional injection	Reduced wound area and increased re-epithelialization rate	[376]
EGF	Topical spray	Faster healing velocity and higher complete healing rate	[377]
EGF	Topical hydrogel	78% of wounds healed after 30 d	[378]

CGS: Collagen/gelatin spong; rhVEGF: Recombinant human vascular endothelial growth factor; PDGF: Platelet-derived growth factor; EGF: Epidermal growth factor; FGF: Fibroblast growth factor.